Serum levels of S100A12 and S100A8/A9 were shown to be increased in various inflammatory and autoimmune diseases, and complement activation was reported to occur at sites expressing S100A8/A9 [30, 31, 35–37]. Here, S100A12 is linked to autoimmune disease.